<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-DCN7RN2V/214ccca3-e1e3-41ff-9921-1f82fc74f24b/HTML"><dcterms:extent>31 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-DCN7RN2V/5d0331d9-fc4e-4c51-8d7e-b9ce9d398c0f/PDF"><dcterms:extent>194 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-DCN7RN2V/400e917d-35ca-46cb-a64a-69885d350c48/TEXT"><dcterms:extent>28 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-DCN7RN2V"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2005</dcterms:issued><dc:creator>Globočnik Petrovič, Mojca</dc:creator><dc:creator>Preskar, Andrejka</dc:creator><dc:format xml:lang="sl">številka:10</dc:format><dc:format xml:lang="sl">letnik:74</dc:format><dc:format xml:lang="sl">str. 607-611</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:20410073</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-DCN7RN2V</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="en">Etiology</dc:subject><dc:subject xml:lang="sl">mrežnica</dc:subject><dc:subject xml:lang="sl">očesne bolezni</dc:subject><dc:subject xml:lang="sl">oftalmologija</dc:subject><dc:subject xml:lang="en">Therapy</dc:subject><dc:subject xml:lang="en">Vitrectomy</dc:subject><dc:subject xml:lang="sl">Vitrektomija</dc:subject><dc:subject xml:lang="en">Vitreoretinopathy, Proliferative</dc:subject><dc:subject xml:lang="sl">Vitreoretinopatija proliferativna</dc:subject><dc:subject xml:lang="sl">zdravljenje</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Proliferativna vitreoretinopatija| Proliferative vitreoretinopathy|</dc:title><dc:description xml:lang="sl">Background. Proliferative vitreoretinopathy (PVR) is a disease characterized by formation of membranes on both surfaces of the retina and vitreous base. PVR is a wound healing response which is inadequate and uncontrolled in the eye. Identifying the risk factors is important for PVR prediction. The distinction between anterior and posterior PVR is essential in predicting the surgery success. Conclusions. The anatomic and first of all functional successafter vitrectomy are relatively poor. To improve the outcome the research has been focused on the use of pharmacological agents to prevent the development of PVR. A combination of 5-fluorouracil and low molecular weight heparin is the only proven effective therapy for PVR prevention</dc:description><dc:description xml:lang="sl">Izhodišča. Proliferativna vitreoretinopatija (PVR) je bolezen, za katero je značilen razvoj kontraktilnih membran na notranji in zunanji površini mrežniceter na bazi steklovine. Gre za proces celjenja rane, ki pa je zaradi specifičnih anatomskih razmer v očesu neprimeren in nenadzorovan. Za napoved PVR moramo poznati dejavnike tveganja. Razlikovanje med anteriorno in posteriorno obliko PVR je pomembno pri napovedi uspešnosti operacije. Uspešnost operativnega zdravljenja je boljša pri posteriorni kot anteriorni obliki. Zaključki. Zaradi slabega anatomskega in predvsem funkcionalnega izidapri očeh s PVR je pomemben cilj preprečevanje PVR. Znanstveno raziskovanje je usmerjeno v iskanje farmakoloških substanc, ki bi preprečile razvoj PVR. Edino doslej uspešno farmakološko zdravljenje za preprečevanje PVRje kombinacija zdravil 5-fluorouracila in nizkomolekularnega heparina</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-DCN7RN2V"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-DCN7RN2V" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-DCN7RN2V/5d0331d9-fc4e-4c51-8d7e-b9ce9d398c0f/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-DCN7RN2V/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-DCN7RN2V" /></ore:Aggregation></rdf:RDF>